Jennison Associates
CRBP icon

Jennison Associates’s Corbus Pharmaceuticals CRBP Stock Holding History

Jennison Associates’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-6,894
Closed -$1.26M – 665
2018
Q1 		$1.26M Sell
6,894
-606
-8% -$136K ﹤0.01% 550
2017
Q4 		$1.6M Buy
+7,500
New +$1.61M ﹤0.01% 559

Other funds holding CRBP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Jennison Associates's CRBP Position: Q2 2018 in Review

Jennison Associates sold out of Corbus Pharmaceuticals (CRBP) in Q2 2018, closing a stake of 6,894 shares — an estimated $1.26M sold.

Jennison Associates first reported a position in CRBP in Q4 2017 and held it in 2 quarters. The position peaked at $1.6M in Q4 2017. 81 funds tracked by Wall St. Rank hold CRBP as of Q2 2018.

  • Jennison Associates reported no remaining Corbus Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Jennison Associates sold 6,894 Corbus Pharmaceuticals shares in Q2 2018, an estimated $1.26M.
  • Jennison Associates first reported a position in Corbus Pharmaceuticals in Q4 2017 and held it in 2 quarters.
  • Jennison Associates's Corbus Pharmaceuticals position peaked at $1.6M in Q4 2017.
  • 81 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2018.

Based on Jennison Associates's 13F filing for Q2 2018, filed 2 Aug 2018.